EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Clinical trial NCT06997588 · RECRUITING
Trial details
- NCT number
- NCT06997588
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-09
- Primary completion
- 2028-08-02
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.